rhGAD65

rhGAD65 Uses, Dosage, Side Effects, Food Interaction and all others data.

rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.

The immune system of patients treated with rhGAD65 demonstrate an increase in the secretion of several immunomodulatory substances, dominated by regulatory cytokines, including IL5, IL13, IL10, IL17, IFN-a and TNF-a. Additionally, the activity of T-cells in response to GAD65 is increased with rhGAD65 therapy and subjects receiving rhGAD65 show an up regulation of cytokines in response to GAD65.

Table Of contents

• rhGAD65
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	rhGAD65
Generic	rhGAD65
rhGAD65 Other Names	Recombinant human GAD65, Recombinant human glutamic acid decarboxylase
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in diabetes mellitus type 1.

Innovators Monograph

You find simplified version here rhGAD65